NFKB1 and cancer: Given that the activation of NF-κB can drive STING-dependent tumorigenic responses while inhibiting a Type I-IFN anti-cancer response, it is critical to understand how STING agonists not only impact STING signalling but also RECON signalling, which unfortunately is overlooked in virtually all studies on STING agonists.